32 results on '"Ennishi, Daisuke"'
Search Results
2. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
3. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
4. Supplementary Table S12-14 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
5. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
6. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
7. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
8. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
9. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
10. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
11. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
12. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
13. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
14. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
15. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
16. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
17. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
18. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
19. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
20. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
21. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
22. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
23. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
24. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
25. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
26. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
27. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
28. Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma
29. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
30. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
31. Abstract IA18: Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma
32. An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.